Start here · since 1996

Psychedelics Guide

More than 500 articles organized by substance and topic: psilocybin, LSD, ayahuasca, DMT, MDMA, mescaline and harm reduction. Rigorous information, without fear and without propaganda.

Featured articles

Explore the largest archive on psychoactive substances, published since 1996

US Psychedelic Helpline: Insights from 25,419 Interactions

A Science Advances paper details 25,419 contacts with the Fireside Project (2021-2026), primarily regarding psilocybin and trip support. Among interactions with recorded history, 2.4% mentioned schizophrenia. The data reflects only those who reached out.

Persistent difficulties after psychedelics or meditation: Emory publishes a protocol for a 1,600-person study

A team led by Emory University has posted on medRxiv the protocol for an observational study that will follow, for one year, people who attribute persistent difficulties to psychedelics or meditation. It is a research plan with no data. The sample is deliberately recruited among affected people, so it is not designed to estimate how often these problems occur.

Mind & Spirit

Inspiring reads for open minds

From our readers

Articles chosen by our community of readers

Send us your story and get featured on our homepage

Hofmann and Huxley: LSD Between Serendipity and Vision

Albert Hofmann recounts the discovery of LSD and his personal friendship with Aldous Huxley, examined through historical context and critical reflection.

Cannabis and Self-Awareness: How It Alters the Sense of Self

How cannabis can alter the sense of self: corollary discharge, depersonalization, and self-awareness, including their neural basis and a critical review.

Eleusis and the Kykeon: Hofmann’s Ergot Hypothesis

Our series on Albert Hofmann continues. Here, we examine the thesis he developed alongside Wasson and Ruck regarding the substance used in the ancient Eleusinian mysteries: an ergot-derived drug closely related to LSD.
portadalibrohofmannpequena

LSD: Dr. Albert Hofmann's Medicine

Ibogaine Legality and Clinics Worldwide: What We Know

Ibogaine shows promise in treating addiction and trauma. We review its legal status by country, the state of clinics, and associated cardiac risks.

Methylphenidate and ADHD: Formulations and Diagnostic Doubts

We continue our look at methylphenidate. In our previous installment, we began discussing the drug and focused on the most well-known commercial presentation, typically prescribed to children with Attention Deficit Hyperactivity Disorder (ADHD). This product is fast-acting, with effects lasting three to six hours, requiring at least twice-daily dosing to cover the subject's active hours.

News

The latest from the psychedelic world

Latest articles

Browse our most recent articles